BRAF mutation in papillary thyroid carcinoma
BRAF mutation in papillary thyroid carcinoma
复制标题
DOI：
10.1093/jnci/95.8.625
复制
发表时间：
2003-04-16
期刊：
影响因子：
--
通讯作者：
Sidransky, D
中科院分区：
文献类型：
--
作者：
Cohen, J;Xing, MZ;Sidransky, D
已经发现BRAF基因被人类癌症突变激活，主要是恶性黑色素瘤。我们测试了476个原发性肿瘤，包括214个肺，126头和颈部，54个甲状腺，27个膀胱，38个宫颈癌和17个前列腺癌，用于BRAF T1796a通过聚合酶链反应（PCR） - BRAF EXON EXON EXON 15的限制性分析。在检查的35个甲状腺癌中，有24个（69％）在BRAF基因（T1796a）的核苷酸1796年的1796年trymine（T） - >腺嘌呤（a）横断性。在四个肺癌和六个头颈部癌症中检测到T1796A突变，但在膀胱，宫颈或前列腺癌中检测到。我们的数据表明，激活BRAF突变可能是乳头状甲状腺癌发展的重要事件。
The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)-->adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer.